Positron clinches Cadenza exclusivity:
This article was originally published in Clinica
Positron, the Houston, Texas-based specialist in positron emission tomography (PET) products, has gained exclusive licensing rights to sell and further develop the Cadenza diagnostic data acquisition software. The computer programme, developed by Dr George Diamond, uses Bayes' theorem to help doctors analyse and report results of various diagnostic tests associated with coronary artery disease, enabling them to assess more accurately a patient's risk and probability of developing coronary heart disease.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.